Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences names Richard Markus Chief Medical Officer, Dimitry Nuyten departs

Neutral Impact 3 of 5 leadership Written later

Arcus Biosciences said Richard Markus, M.D., Ph.D. will become Chief Medical Officer effective January 31, 2025, and that Dimitry Nuyten, M.D., Ph.D. will leave the company on the same date. Nuyten entered into a separation agreement under the company's Severance Benefits Plan that includes a lump sum payment equal to 12 months of base salary, COBRA coverage for up to 12 months, and an additional cash payment tied to his 2024 annual bonus. The filing does not disclose the dollar amounts of these payments.

Key points

  • Richard Markus, M.D., Ph.D. appointed Chief Medical Officer, effective January 31, 2025
  • Dimitry Nuyten, M.D., Ph.D. departs January 31, 2025
  • Severance includes a lump sum equal to 12 months of base salary and COBRA coverage for up to 12 months
  • Additional cash payment tied to Nuyten's 2024 annual bonus; the final separation agreement will be filed after execution

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECJan 21, 2025, 4:11 PM ET
Accession number0001724521-25-000005

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.